FORMULATION AND EVALUATION OF LIDOCAINE HYDROCHLORIDE CHEWABLE TABLET by Kasar, Harshada Anil et al.
Vol 11, Issue 11, 2018
Online - 2455-3891 
Print - 0974-2441
FORMULATION AND EVALUATION OF LIDOCAINE HYDROCHLORIDE CHEWABLE TABLET
HARSHADA ANIL KASAR1*, ASISH DEV1, SUBHAKANTA DHAL3
1Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India. 2Deputy Manager, Laurus Lab, 
Hyderabad, Telangana, India. Email: rxharshadakasar@gmail.com
Received: 2 May 2018, Revised and Accepted: 4 July 2018
ABSTRACT
Objective: The objective of this study was to formulate and optimize a chewable formulation of lidocaine hydrochloride using a 32 factorial design for 
optimized the superdisintegrant concentration.
Methods: Various concentrations of sodium starch glycolate (SSG) (13.33 mg, 26.66 mg, and 40 mg) of superdisintegrant and starch (50 mg, 83 mg, 
and 116.66 mg) were added in the formulation; nine formulations were prepared according to 32 factorial designs and evaluated. The responses were 
analyzed for analysis of variance using Design-Expert version 10 software. Statistical models were generated for each response parameter. The models 
were tested for significance. Procedure to manufacture chewable tablets by direct compression was established.
Results: The results show that the presence of a superdisintegrant is desirable for chewable formulation. The best-optimized batch F7 found the batch 
having starch of amount 116.66 mg and SSG 13.33 mg. All the prepared batches of tablets were within the range. Optimized batch F7 showed drug 
content 102.46±0.0543, wetting time 18±1.7320, friability 0.65±0.0216, and drug release rate 99.97±0.0124% at the end of 30 min.
Conclusion: It can be concluded that 32 full factorial design and statistical models can be successfully used to optimize the formulations, and it was 
concluded that the trial batch F7 is the optimized formulation which compiles official specifications of chewable tablets. The optimized batch was 
evaluated for thickness, weight variation, hardness, friability, drug dissolution, and stability study for 3 months. The similarity factor was calculated 
for comparison of dissolution profile before and after stability studies. After 30 min the drug release rate for batch F7 was 98.97% (Table 6). Hence, 
the results of stability studies reveal that the developed formulation has good stability.
Keywords: Lidocaine hydrochloride, Chewable tablet, Sodium starch glycolate.
INTRODUCTION
Chewable tablets are designed for use by the children and such person 
who may have difficulty in swallowing the tablets. In addition, chewable 
tablets facilitate more rapid release and have more rapid absorption of 
the active ingredients, provide quick onset of action. Hence, it was decided 
to formulate robust, effective, and complaint chewable dosage form of 
lidocaine hydrochloride (HCl) for providing painless dentistry without 
needle, potentially decreasing the number of dental phobic patients. 
Dental disorders are usually associated with inflammation and moderate-
to-severe pain. Lidocaine, amide derivative, is a safe anesthetic agent 
possesses a mild local anesthetic effect. Thus, it was attempted to design 
chewable tablet containing lidocaine HCl, mainly for the treatment of 
dentistry and enhanced patient compliance are of paramount importance.
EXPERIMENTAL
Materials
Lidocaine hydrochloride provided by Aurobindo Pharma, Hyderabad 
and other ingredients included Lactose monohydrate, starch, sodium 
starch glycolate, manitol, aspartame, mint flavor, talc, aerosil.
Methods
Formulation design [11,13]
Formulation development by direct compression method
All the ingredients were separately weighed and shifted using mesh 
no 40. Lidocaine, lactose monohydrate, starch, SSG, and mannitol were 
passed through mesh no 30 aspartame and mint flavor were passed 
through 100 mesh and required quantities were blended for 10 min. 
Finally, the above blend was lubricated with magnesium stearate, 
talc, and aerosil for 2 min. The powder blend was evaluated for the 
flow properties and was found to be good. The evaluated blend was 
compressed into tablets of 563 mg weight each. Minimum of 50 tablets 
was prepared for each batch. The manufacturing formulas for the 
tablets used in the above method are given in Table 2.
Optimization of process variables
It is desirable to develop an expectable pharmaceutical in the shortest 
period of time using minimum workforce and raw materials. In 
addition to the art formulation, full factorial design is an efficient 
method of indicating the relative significance of a number of variables 
and their interaction. Batches were made with the aid of factorial 
design. In the present study, effect of two variables was considered. 
Two variables were considered at three levels lower level (1), middle 
level (0), and upper level (+1); hence, it was 32 factorial design. 
Shown in table 1.
Based on initial trials, levels of starch were selected as 50, 83, and 
116.66 mg, whereas SSG levels were 13.33, 26.66, and 40 mg, nine 
formulations were prepared according to 32 factorial designs and 
evaluated. The responses were analyzed for analysis of variance 
(ANOVA) using Design-Expert version 10 software. Statistical models 
were generated for each response parameter. The models were tested 
for significance.
Evaluation of granules
Untapped bulk density [1]
About 10 g powder was placed into 100 ml measuring cylinder. Volume 
occupied by the powder weight is noted without disturbing the cylinder 
and bulk density is calculated by the following equation;
Untapped bulk density = Mass of bulk drug/Volume of bulk drug [8]
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Tapped bulk density [4]
About 10 g powder was placed into 100 ml measuring cylinder. The 
cylinder is then subject to a fixed number of taps (~100 times) until the 
powder bed volume goes to the minimum level. Record the final volume 
and calculate the tap density by following equation;
Tapped bulk density = Mass of bulk drug/Volume of bulk drug on 
tapping [8]
Compressibility index [8]
It is an important measure obtained from bulk density and isdefined 
as:
C=Þb−Þu/Þb×100
Where, Þb=Tapped density of powder
Þu=Bulked density of powder
If the particle bed is more compressible, the blend will be less flowable 
and flowing materials.
Hausner’s ratio [8]
Hausner’s of the drug is found out using the following formula:
Hausner’s ratio=Bulk density/Tapped density
Angle of repose [8]
The frictional force of a powder can be measured by the angle of repose. 
It is defined as the maximum angle possible between the pile’s surface 
of the powder and the horizontal plane. If more powder is added to the 
pile, it slides down the sides of the pile until the friction of the particles 
producing a surface angle, which is in equilibrium with the force of 
gravitation.
The angle of repose was determined by the funnel method suggested by 




h=Height of the cone
r=Radius of the cone base
Angle of repose <30° shows the free flowing of the material.
Evaluation of chewable tablet
General appearance
The general appearance of a tablet is its visual identity and overall 
“elegance” is essential for consumer acceptance. General appearance 
includes tablet’s size, shape, color, presence or absence of any odor, 
taste, surface texture, physical flaws and consistency, and legibility of 
any identifying marking [2].
Size and shape
The size and shape of the tablet could be dimensionally described, 
monitored, and controlled [2].
Hardness
The hardness of the tablet from each formulation was determined using 
Monsanto type hardness tester. A significant strength of chewable tablet 
is difficult to achieve due to the specialized processes and ingredients 
used in the manufacturing. The limit of hardness for the chewable 
tablet is usually kept in a lower range to facilitate rapid disintegration 
in the mouth [7].
Weight variation [6]
A total of 20 tablets were selected randomly from the lot and weigh 
individually to check for weight variation. Weight variation specification 
as per I.P. is shown as follows:
Tablet thickness
Thickness was calculated using digital Vernier calipers. 10 tablets were 
taken and thickness was measured by micrometer [6].
Friability [7]
It is measured of mechanical strength of tablets. Roche friabilator was 
used to determine the friability. A preweighed tablet was placed in the 
friabilator. Friabilator consists of a plastic chamber that revolves at 25 rpm, 
dropping those tablets at a distance of 6 inches with each single revolution. 
The tablets were rotated in the friabilator for at least 4 minutes. At the end 
of test, tablets were dusted and reweighed; the loss in the weight of tablet 
is the measure of friability and is expressed in percentage as:
% friability=(loss in weight/initial weight)
Dissolution test [10]
In vitro dissolution studies for all the fabricated tablets were carried out 
using USP Type II apparatus at 50 rpm in 500 ml of phosphate buffer 
Table 1: Summarizes the independent and dependent variables along with their coded and actual levels
Factors (independent variables) Levels used Response dependent variable
−1 0 1
A: Concentration of Starch 50 mg 83 mg 116.66 mg % Cumulative drug release
B: Concentration sodium starch glycolate 13.33 mg 26.66 mg 40 mg
Table 2: Composition of chewable tablets as per 32 factorial design to achieve maximum % drug release within 30 min
Ingredients F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) F6 (mg) F7 (mg) F8 (mg) F9 (mg)
Lidocaine 200 200 200 200 200 200 200 200 200
Lactose monohydrate 163.33 150 136.66 130 116.66 103.33 96.66 83.33 70
Starch 50 50 50 83 83 83 116.66 116.66 116.66
Sodium starch glycolate 13.33 26.66 40 13.33 26.66 40 13.33 26.66 40
Mannitol 100 100 100 100 100 100 100 100 100
Aspartame 10 10 10 10 10 10 10 10 10
Mint flavor 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Talc 6 6 6 6 6 6 6 6 6
Aerosil 12 12 12 12 12 12 12 12 12
Total weight 563 563 563 563 563 563 563 563 563
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pH 6.8, maintained at 37±0.5°C for 30 min. 5 ml aliquot was withdrawn 
at the 5 time intervals, filtered through Whatman filter paper and 
assayed spectrophotometrically at 263 nm using Veego VDA6D 
spectrophotometer. An “equal volume of phosphate buffer pH 6.8,” which 
was prewarmed at 37°C was replaced into the dissolution medium after 
each sampling to maintain the constant volume throughout the test [9].
RESULTS AND DISCUSSION
The formulations were evaluated for pre-compression parameters 
and the values were found to be within the prescribed limits for all 
formulations. The angle of repose indicates good flow property for all 
the formulations. The results were presented in Table 3. IR spectroscopic 
studies indicated that the drug is compatible with all the excipients. The 
IR spectrum of lidocaine HCl and lidocaine HCl formulation containing 
higher proportion of excipients was found to be similar fundamental 
peaks and patterns, thus confirming that no interaction of drug occurred 
with the components of the formulation. The general appearance of 
formulated tablets was examined. The formulated tablets were found 
to be elegance in appearance, without any surface damage. The tablets 
possessed uniform size and shape. The compressed tablets were 
evaluated for various physical parameters such as diameter, thickness, 
hardness, friability, uniformity of the weight, and drug content. The 
results are presented in Table 4. The diameter of the tablets was found 
in the range of 12.03±0.0124 mm–12.06±0.0173 mm, and thickness was 
found in the range of 5.04±0.0124 mm–5.39±0.0294 mm. The hardness 
was found to be in the range of 4.2±0.1241 kg/cm2–6.4±0.0816 kg/cm2. 
The percentage friability of all formulations was found in the range of 
0.64±0.0124%–0.72±0.0167% and value <1% is an indication of tablet 
with good mechanical resistance. The weight of one tablet is 563 mg and 
the acceptable deviation was ± 5%. The weight of all tablets was found 
to be uniform and within the acceptable limit. The drug content of all 
the tablets was found in the range of 96.52±0.0169%–102.46±0.0543%, 
which was within the acceptable limits (Table 4).
A total of nine formulations were formulated from F1 to F9. For 
formulation F1, F4, and F7, the drug was mixed with lower amount of 
SSG, i.e., 13.3 mg and starch 50 mg, 83 mg, and 116.66 mg, respectively, 
showing 95.78±0.0294%, 99.44±0.0205%, and 99.97±0.0124% 
drug release in 30 min. In case of formulation F2, F5, and F8, the 
drug was mixed with SSG 26.66 mg and starch 50 mg, 83 mg, and 
Table 3: Pre‑compression evaluation parameters of lidocaine HCl tablets
Formulation Angle of repose Loose bulk density (g/cc) Tapped bulk density (g/cc) Percent compressibility Hausner’s ratio
F1 36.52±0.0081 0.467±0.0418 0.7006±0.0081 33.2833±5.2910 1.4980±0.1184
F2 33.69±0.0235 0.5000±0.0216 0.6653±0.0104 25.2566±1.7450 1.3200±0.0637
F3 36.52±0.0565 0.5033±0.0169 0.769±0.0032 34.9833±2.2578 1.5380±0.0053
F4 35.53±0.0509 0.477±0.0088 0.714±0.0016 33.1333±1.6456 1.4953±0.0294
F5 33.69±0.0374 0.4543±0.0154 0.714±0.00081 25.9733±0.2735 1.5733±0.0531
F6 33.69±0.0849 0.5003±0.0175 0.6663±0.0020 25.0200±1.7578 1.3323±0.0531
F7 33.69±0.0535 0.4766±0.0122 0.7146±0.0033 33.3366±1.7228 1.5001±0.0496
F8 35.53±0.1203 0.5000±0.0138 0.668±0.0065 25.2533±1.7078 1.3266±0.0286
F9 36.52±0.0432 0.5266±0.0036 0.7693±0.0044 31.5700±1.1920 1.4615±0.0216
HCl: Hydrochloride
Table 4: Post‑compression evaluation parameters of lidocaine HCL chewable tablets










F1 +++ 5.04±0.0124 6.4±0.0816 0.72±0.0167 12.05±0.0124 493±2.1602 21±2.5166 99.86±0.7190
F2 +++ 5.29±0.0163 6.3±0.0816 0.68±0.0124 12.05±0.0163 554±1.6329 22±1.7320 99.24±0.3766
F3 +++ 5.17±0.0262 5.8±0.0816 0.69±0.0124 12.04±0.0124 501±1.7320 23±4.0824 98.40±0.3350
F4 +++ 5.39±0.0294 5.9±0.0816 0.64±0.0124 12.06±0.0173 517±1.7320 19±2.5166 98.70±0.0821
F5 +++ 5.37±0.0169 5.6±0.3559 0.66±0.0124 12.04±0.0270 542±1.2909 22±2.1602 96.52±0.0169
F6 +++ 5.37±0.0205 5.7±0.0816 0.68±0.0169 12.04±0.0081 542±2.4494 24±4.0414 98.99±1.7720
F7 +++ 5.32±0.0047 5.9±0.0816 0.65±0.0216 12.03±0.0205 560±2.7080 18±1.7320 102.46±0.0543
F8 +++ 5.32±0.0081 4.2±0.1241 0.66±0.0216 12.03±0.0169 559±2.0876 20±1.2909 100.45±0.3366
F9 +++ 5.32±0.0081 4.5±0.1241 0.68±0.0124 12.03±0.0124 556±1.6329 25±2.1602 96.25±0.6313
Mean±SD, n=3. +: Poor, ++: Acceptable, +++: Good, HCl: Hydrochloride, SD: Standard deviation
Fig. 1: Drug release profile of formulation F1–F5
Fig. 2: Drug release profile of formulation F6–F9
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116.66 mg, respectively, showing 95.20 ±0.0374%, 94.30 ±0.0124%, 
and 99.19 ±0.0612%. In case of formulation F3, F6, and F9, the drug 
was mixed with higher amount of SSG, i.e. 40 mg and starch 50 mg, 
83 mg, and 116.66 mg showing 91.44±0.0124%, 89.81±0.0124%, and 
88.17±0.0124%, respectively. Formula F7 was optimized the batch that 
shows drug highest drug release 99.97± 0.0124%.
Assay (% drug content)
Transfer accurate measured quantity of tablet, equivalent to about 
150 mg of lidocaine HCl, to 125 ml of conical flask, and protects from 
atmospheric moisture with stopper fitted with a tube containing silica 
gel. Add 20 ml of glacial acetic acid and two drops of crystal violet. 
Titrate immediately with 0.1 N perchloric acid VS to a blue end point. 
Perform a blank determination and make necessary correction. Each 
ml of 0.1 N perchloric acid is equivalent to 23.43 mg of C14H22N2O5 
(Figs. 1 and 2).
Stability studies [12,14]
Stability study of optimized formulation (F7) was conducted for 
3 months. The dissolution, drug content of chewable tablets was tested 
each month, and the values of these evaluation parameters have been 
mentioned in Table 5. No significant change was found on comparing 
the values of evaluation parameter before and after the stability study. 
Thus, formulation was indicated to be stable.
ANOVA for response surface linear model
The model F value of 17.15 implies the model is significant, shown in 
table 7. There is only a 0.46% chance that an F value this large could 
occur due to noise. Values of “p>F” <0.0500 indicate that model terms 
are significant. In this case B, AB is significant model terms. Values 
>0.1000 indicate that the model terms are not significant. If there 
are many insignificant model terms (not counting those required to 
support hierarchy), model reduction may improve model.
The “Pred R2” of 0.6642 is in reasonable agreement with the “Adj R2” 
of 0.8583; i.e. the difference is <0.2. “Adeq Precision” measures the 
signal-to-noise ratio. A ratio >4 is desirable. Ratio of 13.638 indicates 
an adequate signal (Table 8). This model can be used to navigate the 
design space.
Final equation in terms of coded factors
%CDR=+109.56333−1.20500*Starch−4.01667*Sodium starch glycolate
The equation in terms of actual factors can be used to make predictions 
about the response for given levels of each factor. Here, the levels should 
be specified in the original units for each factor. This equation should 
not be used to determine the relative impact of each factor because the 
coefficients are scaled to accommodate the units of each factor, and the 
intercept is not at the center of the design space. Shown in Fig. 3 
Fig. 3: Response three‑dimensional surface plot for percent drug 
release at 30 min
Table 5: Stability studies data of lidocaine HCl tablets
Parameters Thickness (mm) Hardness  
(kg/cm2)





After 1 month 5.31 5.9 0.64 12.03 560 17 101.66
HCl: Hydrochloride
Table 6: Drug release profile of optimize F7 batch
Time interval After 0  
min (%)
After 5  
min (%)
After 10  
min (%)
After 15  
min (%)






After 1 month 0 16.20 34.80 50.69 74.70 98.60 98.97
Table 7: Analysis of variance table (Partial sum of squares ‑ Type III)
Source Sum of square df value Mean square F value p value P>F
Model 323.08 3 107.69 17.15 0.0046 Significant
A Starch 8.71 1 8.71 1.39 0.2918
B sodium starch glycolate 96.80 1 96.80 15.42 0.0111
Residual 217.56 1 217.56 34.65 0.0020
Cor total 31.40 5 6.28
354.47 8
Table 8: Regression output of R1 for 32 full factorial design
Parameters Value Parameters Value
Std. dev. 2.51 R2 0.9114
Mean 109.56 Adj-R2 0.8583
C.V% 2.29 Pred R2 0.6642
PRESS 119.02 Adeq precision 13.638
−2 log likelihood 36.79 BIC 45.58
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From actual factor equation and counterplot of percentage drug release 
versus independent variable, it was concluded that as amount of SSG 
decreases percentage drug release is increases.
All the prepared batches of tablets were within the range. Using 
Monsanto hardness tester, the strength of the tablets was tested. All 
the tablets showed good hardness. Batch F8 had minimum hardness 
4.2 while F1 had maximum hardness 6.4. The friability was carried out 
for all the batches of tablets. The friability was <0.2% for all the blends 
and was satisfactory. Assay value of all prepared batches of lidocaine 
HCl tablets was within the range of 95%–105% of stated amount of 
lidocaine HCl. From the data obtained, drug release rate at 30 min for 
batches F1, F2, F3, F4, F5, F6, F7, F8 and F9 was found 95.78±0.0294%, 
95.20±0.0374%, 91.44±0.0124%, 99.44±0.0205%, 94.30±0.0124%, 
89.81±0.0880%, 98.97 ±0.0124%,  99.19±0.0612%, 88.17±0.0124% 
respectively. Shown in Fig 1
From all obtained results, it was found that trails F1, F2, F3, F4, F5, F6, 
F8, and F9 show slow drug release up to 30 min, but the trail F7 was the 
best one shows almost 100% drug release at the end of 30 min which 
formulated with 2.4% of SSG and 21% of starch having 102.46% drug 
content.
CONCLUSION
Chewable tablet could be successfully prepared by direct compression 
method using lactose monohydrate, starch, SSG, mannitol, aspartame, 
mint flavor, talc, and aerosol whose response was excellent. In vitro 
release rate studies showed that the drug release for chewable tablet 
was maximum in formulation F7 is 99.97±0.0124% at the end of 30 min.
Finally, it can be concluded that 32 full factorial design and statistical 
models can be successfully used to optimize the formulations, and it 
was concluded that the trial batch F7 is the optimized formulation 
which compiles official specifications of chewable tablets. The lidocaine 
HCl chewable tablet with formulation F7 concluded that the robust, 
effective, and reproducible formula with local anesthetic action and 
drug release.
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